TPAG organizes Thalassemia & SCD prevention discussion
The policymakers, doctors and, patient bodies discuss ways to implement thalassemia control programme nationally
The policymakers, doctors and, patient bodies discuss ways to implement thalassemia control programme nationally
Q4 results was challenging driven by steep fall in CDMO revenues and higher upfront cost of Capex projects and R&D projects
Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country
The company has posted net profit of Rs.464.4 crores for the Financial Year ended March 31, 2023
The R&D Center significantly increases Siegfried’s R&D capacity to drive further growth
The funding will be used to expand the product line for remote patient monitoring and to scale the business across Asia and Africa
Bridging the gap between histopathology and molecular pathology
New high-tech facility in Biberach offers attractive workplaces for more than 500 scientists
Subscribe To Our Newsletter & Stay Updated